A Prolonged Recovery Reaches a New Peak

Teva’s stock continues to lead trading in Tel Aviv, registering another day of gains. The share is up 1.37% at 9529 agorot, surpassing the previous 52-week high of 9535 agorot reached in recent sessions. The message from the market is clear: Teva, once struggling under significant challenges, is firmly back in the spotlight with momentum supported by tangible progress.

The three-year cumulative rise of 229.61% reflects a long-term shift driven by operational stabilization, improved management, and strengthened performance in core segments. Short-term indicators also reflect confidence: a three-month return of 45.1% and a year-to-date gain of 17.63% position Teva among the strongest names in the Tel Aviv indices.

Trading Data Reflecting Confidence

Current trading volume stands at roughly NIS 84 million, nearly identical to the quarterly daily average, showing consistent and elevated interest from both retail and institutional investors. Bid-ask depth indicates persistent demand near current price levels, signaling belief in continued upward momentum.

Teva’s sensitivity to the Tel Aviv indices reinforces this momentum. The stock accounts for 8.97% of the TA-35 and 6.58% of the TA-125—substantial weights that position it as a core holding across diversified portfolios.

Financial Results Signaling a Turning Point

Teva’s Q3 2025 results are a central driver of the rally. Revenue reached $4.49 billion, marking an increase year over year, while operating income rose to $1.07 billion. The standout figure is net income: $435 million, compared with a loss of approximately $438 million in the same quarter last year.

This sharp turnaround reflects several factors:
• Reduced operating and legal expenses.
• Improved stability in the generics market alongside continued growth in specialty products.
• Significant contribution from key therapeutic areas such as migraine, multiple sclerosis, and oncology.

On an annual basis, the figures also signal continued recovery. Following a full-year loss in 2024, the trajectory for 2025 points toward substantial improvement and a possible return to profitability.

Insider Activity Shows Mixed Movement

Insider transaction data reveals two contrasting trends. Fidelity remains one of the largest shareholders with a 7.23% stake, while some executives and related parties executed sales earlier in 2025. Nonetheless, these sales do not alter the broader picture: institutional participation remains strong, demonstrating confidence in Teva’s long-term trajectory.

A Central Force in TA Indices

Teva continues to strengthen its weight in Israel’s primary equity indices, particularly the TA-35, where it is one of the heaviest constituents. A nearly 9% index weight not only marks Teva as a sector leader but also directly affects the allocation of hundreds of billions of shekels managed across the local market.

Index performance figures show strong monthly gains—typically between 4% and 7%—with Teva serving as a key driver of these positive moves.

Conclusion

Teva is demonstrating that its strategic realignment, coupled with improved financial performance, has restored confidence and repositioned the company at the center of Israeli capital markets. With strong performance, rising profitability, consistent trading demand, and a break to new yearly highs, the stock is reasserting itself as a leading force in the domestic pharma sector.

Still, despite the positive momentum, the company operates in a highly competitive environment that continues to demand efficiency, innovation, and disciplined financial management. Teva has shown over the past year that it can meet these challenges, but the path to sustained stability remains a process that will be tested quarter by quarter.